Literature DB >> 8258327

Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo.

A J Ramsay1, M Kohonen-Corish.   

Abstract

Several in vitro studies have shown that murine interleukin-5 (mIL-5) enhances IgA production by activated mucosal B cells. To date, however, there is no evidence that this factor significantly up-regulates mucosal IgA responses in vivo. Here, we show that expression of the gene for mIL-5 in a recombinant vaccinia virus vector markedly increases IgA responses to co-expressed heterologous antigen in the lungs of mice given intranasal inocula of the virus. The elevated local IgA responses to vectors expressing mIL-5 peaked at a fourfold higher level than those elicited by control virus at 14 days after infection and were sustained for at least 4 weeks. Increased IgA responses were abrogated in mice treated with monoclonal antibody against mIL-5 and were not detected in systemic lymphoid tissue. No enhancement of specific IgG levels was found either locally or systemically. Our results indicate that mIL-5 selectively enhances the development of mucosal IgA responses in vivo and suggest that expression of this factor in mucosal vaccine vectors may stimulate local immune reactivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258327     DOI: 10.1002/eji.1830231215

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Studies of immunity and bacterial invasiveness in mice given a recombinant salmonella vector encoding murine interleukin-6.

Authors:  S J Dunstan; A J Ramsay; R A Strugnell
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 3.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Recombinant adenovirus vectors expressing interleukin-5 and -6 specifically enhance mucosal immunoglobulin A responses in the lung.

Authors:  T A Braciak; W S Gallichan; F L Graham; C D Richards; A J Ramsay; K L Rosenthal; J Gauldie
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

Review 5.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus.

Authors:  K H Leong; A J Ramsay; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 7.  Cytokines: the future of intranasal vaccine adjuvants.

Authors:  Afton L Thompson; Herman F Staats
Journal:  Clin Dev Immunol       Date:  2011-07-31

8.  Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice.

Authors:  D L Larsen; N Dybdahl-Sissoko; M W McGregor; R Drape; V Neumann; W F Swain; D P Lunn; C W Olsen
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Influence of Lactobacillus pentosus S-PT84 Ingestion on the Mucosal Immunity of Healthy and Salmonella Typhimurium-Infected Mice.

Authors:  Takayuki Izumo; Fumi Izumi; Ichiro Nakagawa; Yoshinori Kitagawa; Hiroshi Shibata; Yoshinobu Kiso
Journal:  Biosci Microflora       Date:  2011-05-26

10.  Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.

Authors:  P S Foster; S P Hogan; A J Ramsay; K I Matthaei; I G Young
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.